Fulvestrant (FVT)
Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works by down-regulating the estrogen receptor. It is administered as a once-monthly injection. Fulvestrant is a selective estrogen receptor down-regulator (SERD). Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. The dosing schedule for fulvestrant remains under investigation in an attempt to optimize its effectiveness. Fulvestrant provided effective second-line therapy in this setting for postmenopausal women who had relapsed or progressed after previous endocrine therapy.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Fulvestrant (FVT) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Fulvestrant (FVT) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Fulvestrant (FVT) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Fulvestrant (FVT) CLIA Kit Customized Service Offer
n/a ELISA Kit for Fulvestrant (FVT) ELISA Kit Customized Service Offer